Patents by Inventor Pierre-Yves Michellys

Pierre-Yves Michellys has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS
    Publication number: 20210101902
    Abstract: The invention disclosed herein relates to 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds of Formula (A), pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of autoimmune diseases.
    Type: Application
    Filed: December 16, 2020
    Publication date: April 8, 2021
    Inventors: Phillip ALPER, Jonathan DEANE, Songchun JIANG, Tao JIANG, Thomas KNOEPFEL, Pierre-Yves MICHELLYS, Daniel MUTNICK, Wei PEI, Peter SYKA, Guobao ZHANG, Yi ZHANG
  • Compounds and compositions as inhibitors of endosomal toll-like receptors
    Patent number: 10954233
    Abstract: The invention disclosed herein relates to 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds of Formula (A), pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of autoimmune diseases.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: March 23, 2021
    Assignee: NOVARTIS AG
    Inventors: Phillip Alper, Jonathan Deane, Songchun Jiang, Tao Jiang, Thomas Knoepfel, Pierre-Yves Michellys, Daniel Mutnick, Wei Pei, Peter Syka, Guobao Zhang, Yi Zhang
  • COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS
    Publication number: 20190211009
    Abstract: The invention disclosed herein relates to 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds of Formula (A), pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of autoimmune diseases.
    Type: Application
    Filed: September 6, 2017
    Publication date: July 11, 2019
    Inventors: Phillip Alper, Jonathan DEANE, Songchun JIANG, Tao JIANG, Thomas KNOEPFEL, Pierre-Yves MICHELLYS, Daniel MUTNICK, Wei PEI, Peter SYKA, Guobao ZHANG, YI ZHANG
  • Compounds and compositions for modulating EGFR Activity
    Patent number: 9440957
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating EGFR activity, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated EGFR activity.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: September 13, 2016
    Assignee: Novartis AG
    Inventors: Gerald Lelais, Robert Epple, Thomas H. Marsilje, III, Pierre-Yves Michellys, Matthew McNeill, Yun Long, Wenshuo Lu, Bei Chen, Badry Bursulaya, Songchun Jiang
  • Compounds and Compositions for Modulating EGFR Activity
    Publication number: 20150197505
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating EGFR activity, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated EGFR activity.
    Type: Application
    Filed: June 5, 2013
    Publication date: July 16, 2015
    Applicant: IRM LLC, A Delaware Limited Liability Company
    Inventors: Gerald Lelais, Robert Epple, Thomas H. Marsilje, III, Pierre-Yves Michellys, Matthew McNeill, Yun Long, Wenshuo Lu, Bei Chen, Badry Bursulaya Bursulaya, Songchun Jiang
  • Compounds and Compositions for Modulating EGFR Activity
    Publication number: 20150152083
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating EGFR activity, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated EGFR activity.
    Type: Application
    Filed: June 5, 2013
    Publication date: June 4, 2015
    Applicant: IRM LLC, A Delaware Limited Liability Company
    Inventors: Gerald Lelais, Robert Epple, Pierre-Yves Michellys, Badry Bursulaya, Songchun Jiang, Thomas H. Marsilje III, Matthew MCneill
  • COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
    Publication number: 20150105390
    Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
    Type: Application
    Filed: December 17, 2014
    Publication date: April 16, 2015
    Applicant: IRM LLC, a Delaware Limited Liability Company
    Inventors: Pierre-Yves Michellys, Wei Pei, Thomas H. Marsilje, III, Wenshuo Lu, Bei Chen, Tetsuo Uno, Yunho Jin, Tao Jiang
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 8957081
    Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
    Type: Grant
    Filed: September 11, 2012
    Date of Patent: February 17, 2015
    Assignee: IRM LLC
    Inventors: Pierre-Yves Michellys, Wei Pei, Thomas H. Marsilje, III, Bei Chen, Tetsuo Uno, Yunho Jin, Tao Jiang
  • Compounds and compositions as Syk kinase inhibitors
    Patent number: 8722692
    Abstract: Provided herein are a novel class of compounds of Formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated Syk kinase activity.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: May 13, 2014
    Inventors: Jianwei Che, Qiang Ding, Xiaohui He, Hong Liu, Yahua Liu, Pierre-Yves Michellys, Barun Okram, Xu Wu, Kunyong Yang, Xuefeng Zhu
  • FLUOROPHENYL BICYCLIC HETEROARYL COMPOUNDS
    Publication number: 20130338152
    Abstract: The present invention provides a compound the invention, and its use as a IGF-1R inhibitor. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: March 8, 2012
    Publication date: December 19, 2013
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Bei Chen, Robin Alec Fairhurst, Songchun Jiang, Wenshuo Lu, Thomas H. Marsilje, III, Clive McCarthy, Pierre-Yves Michellys, Stefan Stutz
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 8592432
    Abstract: The invention provides novel pyrimidine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, c-ros oncogene (ROS), insulin-like growth factor (IGF-1R), and/or insulin receptor (InsR) or a combination thereof.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: November 26, 2013
    Inventors: Bei Chen, Tao Jiang, Thomas H. Marsilje, Pierre-Yves Michellys, Truc Ngoc Nguyen, Wei Pei, Baogen Wu, Zhaobo Gao, Yonghui Ge, Chen Huang, Yuncheng Li, Xuefeng Zhu
  • Compounds and compositions as kinase inhibitors
    Patent number: 8518931
    Abstract: The invention relates to triazine and pyrimidine derivatives having Formula (1) or (2), and methods for using such compounds. For example, the compounds of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, c-ros oncogene (ROS), insulin-like growth factor (IGF-IR), and/or insulin receptor (InsR) or a combination thereof.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: August 27, 2013
    Assignee: IRM LLC
    Inventors: Tao Jiang, Pierre-Yves Michellys, Truc Ngoc Nguyen, Wei Pei, Baogen Wu, Xuefeng Zhu
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 8399450
    Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: March 19, 2013
    Assignee: IRM LLC
    Inventors: Pierre-Yves Michellys, Wei Pei, Thomas H. Marsilje, Wenshuo Lu, Bei Chen, Tetsuo Uno, Yunho Jin, Tao Jiang
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 8377921
    Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: February 19, 2013
    Assignee: IRM LLC
    Inventors: Pierre-Yves Michellys, Wei Pei, Thomas H. Marsilje, Bei Chen, Tetsuo Uno
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 8372858
    Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
    Type: Grant
    Filed: March 15, 2011
    Date of Patent: February 12, 2013
    Assignee: IRM LLC
    Inventors: Pierre-Yves Michellys, Wei Pei, Thomas H. Marsilje, Bei Chen, Tetsuo Uno, Yunho Jin, Tao Jiang
  • COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
    Publication number: 20130005748
    Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
    Type: Application
    Filed: September 11, 2012
    Publication date: January 3, 2013
    Applicant: IRM LLC
    Inventors: Pierre-Yves Michellys, Wei Pei, Thomas H. Marsilje, Wenshuo Lu, Bei Chen, Tetsuo Uno, Yunho Jin, Tao Jiang
  • Compounds and compositions as modulators of GPR119 activity
    Patent number: 8258156
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.
    Type: Grant
    Filed: May 23, 2011
    Date of Patent: September 4, 2012
    Assignee: IRM LLC
    Inventors: Phillip B. Alper, Mihai Azimioara, Christopher N. Cow, Robert Epple, Pierre-Yves Michellys, Victor Nikulin
  • COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY
    Publication number: 20120196844
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.
    Type: Application
    Filed: March 16, 2012
    Publication date: August 2, 2012
    Applicant: IRM LLC
    Inventors: Phillip B. Alper, Mihai Azimioara, Christopher Cow, Robert Epple, Songchun Jiang, Gerald lelais, Pierre-Yves Michellys, Daniel Mutnick, Victor Nikulin, Lucas Westcott-Baker
  • COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS
    Publication number: 20120184526
    Abstract: Provided herein are a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated Syk kinase activity.
    Type: Application
    Filed: July 30, 2010
    Publication date: July 19, 2012
    Inventors: Jianwei Che, Qiang Ding, Xiaohui He, Hong Liu, Yahua Liu, Pierre-Yves Michellys, Barun Okram, Xu Wu, Kunyong Yang, Xuefeng Zhu
  • ETHER DERIVATIVES OF BICYCLIC HETEROARYLS
    Publication number: 20120165310
    Abstract: The invention relates to compounds of formula I, wherein the substituents are as defined in the specification; to processes for the preparation of such compounds; pharmaceutical compositions comprising such compounds; such compounds as a medicament; such compounds for the treatment of a proliferative disease.
    Type: Application
    Filed: September 10, 2010
    Publication date: June 28, 2012
    Applicant: NOVARTIS AG
    Inventors: Bei Chen, Robin Alec Fairhurst, Andreas Floersheimer, Pascal Furet, Vito Guagnano, Jiang Songchun, Wenshuo Lu, Thomas H. Marsilje, III, Clive McCarthy, Pierre-Yves Michellys, Frederic Stauffer, Stefan Stutz, Andrea Vaupel